Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association


Cyclin A1 is essential for leukemia progression, and its expression is tightly regulated by acinus, a nuclear speckle protein. However, the molecular mechanism of how acinus mediates cyclin A1 expression remains elusive. Here we show that transcription corepressor CtBP2 directly binds acinus, which is regulated by nerve growth factor (NGF), inhibiting its stimulatory effect on cyclin A1, but not cyclin A2, expression in leukemia. NGF, a cognate ligand for the neurotrophic receptor TrkA, promotes the interaction between CtBP2 and acinus through triggering acinus phosphorylation by Akt. Overexpression of CtBP2 diminishes cyclin A1 transcription, whereas depletion of CtBP2 abolishes NGF's suppressive effect on cyclin A1 expression. Strikingly, gambogic amide, a newly identified TrkA agonist, potently represses cyclin A1 expression, thus blocking K562 cell proliferation. Moreover, gambogic amide ameliorates the leukemia progression in K562 cells inoculated nude mice. Hence, NGF downregulates cyclin A1 expression through escalating CtBP2/acinus complex formation, and gambogic amide might be useful for human leukemia treatment.


Nerve growth factor (NGF) is a family member of neurotrophins that are essential for neuronal differentiation and survival (Skaper, 2008). Docking of NGF on its cognate receptor, TrkA, initiates receptor homodimerization, autophosphorylation of cytoplasmic tyrosine residues on the receptor and a cascade of cell-signaling events including Ras/Raf/MAPK, PI3-kinase/Akt and PLC-γ1 (Kaplan and Stephens, 1994). Neurotrophin receptors are also expressed in peripheral tissues. For instance, TrkA is expressed in a variety of leukemia cell lines and primary cells from acute myelogenous leukemia patients (Kaebisch et al., 1996). Nevertheless, NGF signaling and functions in these leukemia cells are not fully understood. TrkA expression in K562 cells is enhanced by differentiation inducer all-trans retinoic acid (Xie et al., 1997), suggesting that NGF might be able to trigger cellular differentiation. Later studies further demonstrate that NGF alone, or in combination with other inducers, actuates K562 megakaryocytic differentiation (Xie et al., 2000). NGF also displays a synergistic effect to cell differentiation in other leukemic cell lines such as Mo-CM and KG-1 (Tsuda et al., 1991). Most recently, we showed that gambogic amide (GA-amide) selectively binds to TrkA cytoplasmic juxtamembrane domain and robustly induces its tyrosine phosphorylation and activates downstream signaling including Akt and MAP kinases. By mimicking NGF, GA-amide exhibits a great neuroprotective role in various neural injury animal models (Jang et al., 2007).

There are two mammalian A-type cyclins, cyclin A1 and A2. Cyclin A1 is limited to male germ cells, whereas cyclin A2 is broadly expressed. Although Cyclin A2 regulates both G1/S and G2/M transition, cyclin A1 is critical for passage of spermatocytes into meiosis I (Wolgemuth et al., 2004). In addition to expression in male germ cells, cyclin A1 is also found in hematopoietic stem cells and primitive precursors (Yang et al., 1997, 1999). Elevated levels of cyclin A1 have been detected in several leukemic cell lines and in patients with myeloid hematological malignancies (Kramer et al., 1998; Yang et al., 1999). Transgenic mouse model reveals that cyclin A1 overexpression results in abnormal myelopoiesis, supporting an important role of cyclin A1 in hematopoiesis and the etiology of myeloid leukemia (Liao et al., 2001).

Acinus (apoptosis chromatin condensation inducer in the nucleus) is a family of nuclear proteins, which trigger chromatin condensation during apoptosis. It has three isoforms (acinus-L, -S and -S′), which have different N-terminal structures that probably arise from alternative splicing (Sahara et al., 1999). During apoptosis, acinus proteins are cleaved by caspases, releasing the active form (p17) to induce chromatin condensation (Sahara et al., 1999). We have shown previously that acinus-S is a substrate of Akt, which phosphorylates acinus on S422 and S573 residues and prevents its apoptotic cleavage (Hu et al., 2005). This cleavage could also be inhibited by the tethering of zyxin, a focal adhesion protein that is constantly translocated into the nucleus, where it provokes the antiapoptotic functions (Kato et al., 2005; Chan et al., 2007). Acinus proteins are also involved in transcription and mRNA splicing. Tange et al. (2005) showed that acinus proteins are components of the exon junction complex, which stabilize the association between RNPS1 and SAP18. Moreover, both acinus-L and -S form a trimeric complex with SAP18 and RNPS1, which functions in inhibiting RNA processing (Schwerk et al., 2003). We have shown recently that acinus-S regulates cyclin A1 transcription in leukemia cells (Jang et al., 2008). This transcription-enhancing activity could be regulated by SRPK phosphorylation. The role of acinus in transcription is further established by showing a direct interaction with retinoic acid receptor (RAR), leading to a repression of RAR-regulated gene (Vucetic et al., 2008).

C-terminal binding proteins (CtBP) are corepressors that inhibit transcription through interaction with a variety of transcription factors. Human and mouse contain two CtBP genes, which encode two proteins (CtBP1 and CtBP2) of high similarity (Katsanis and Fisher, 1998). Structurally, CtBPs share a significant degree of homology to NAD+-dependent dehydrogenase (Kumar et al., 2002), in which the NAD+ binding domain has an important role in the formation of homo- or heterodimers (Thio et al., 2004). Binding of NAD+/NADH also affects the function of CtBPs, thus making the protein as a switch linking cellular redox status to transcription control (Fjeld et al., 2003). For example, association of CtBP2 and neuron restrictive silencing factor is enhanced when cellular NADH concentration is decreased, which results in a repression of brain-derived neurotrophic growth factor expression (Garriga-Canut et al., 2006).

In this report, we show that CtBP2 associates with acinus. This interaction is NAD+ dependent and can be enhanced by NGF stimulation. CtBP2 associates with acinus-S and dampens its cyclin A1 transcriptional enhancing activity. The formation of CtBP2/acinus-S complex is essential for mediating NGF-induced cyclin A1 repression in leukemia cell line K562. Functionally, NGF inhibits K562 cell proliferation in vitro and administration of NGF mimetic GA-amide ameliorates leukemia progression in K562 cells inoculated mice. These results provide a molecular mechanism for the functional role of NGF in leukemia cells and suggest the potential therapeutic application of GA-amide to leukemia treatment.


CtBP2 interacts with acinus-S

To search for the interaction partners of acinus-S, we performed a yeast two-hybrid analysis using the C-terminal domain (amino acids 228–583) as bait. Of the 10 independent positive clones isolated, 1 encodes the C terminus of CtBP2. We observed interactions between the C-terminal portions (CTD) of acinus and CtBP2 regardless of which protein was used as bait or prey. By contrast, the N-terminal portion (NTD) of acinus-S failed to interact with CtBP2 (Table 1). To verify the interaction between these two proteins, we conducted an in vitro binding assay using various recombinant CtBP2 fragments (Figure 1a), and bindings were performed using flag-acinus-S expressed in HEK293 cells. Acinus-S bound independently to the purified NTD of CtBP2 (aa 1–219) and CtBP2 CTD (aa 217–445), fitting with the yeast two-hybrid result. In addition, flag-acinus-S interacted weakly with the CtBP2 mutant lacking the first 48 aa. Surprisingly, intact CtBP2 did not bind to acinus-S in vitro (Figure 1a), indicating that the binding motifs in the NTD and CTD were masked in the full-length protein.

Table 1 Yeast hybrid screening of acinus-S interacting partner
Figure 1

CtBP2 binds acinus-S. (a) Schematic constructs of CtBP2 truncation mutants. Various fragments of GST-tagged CtBP2 were expressed and purified from Escherichia coli. (b) in vitro mapping of the CtBP2 domains that associate with acinus-S. Purified GST-tagged CtBP2 proteins were incubated with lysates of HEK293 cells transfected with flag-tagged acinus-S. The associated acinus-S was pulled down and detected using anti-flag antibody (upper panel). The GST-tagged CtBP2 fragments (asterisked) used in the in vitro binding were detected by Coomassie blue staining (lower panel). (c) Diagram of different deletion mutants of acinus-S. (d) Mapping of acinus-S domains that associate with CtBP2. The C terminus of acinus-S (aa 340–583) was sufficient to bind full-length CtBP2 in transfected cells. The expression of myc-CtBP2 (middle panel) and GST-acinus-S fragments (bottom panel) were verified.

Next, we performed mapping assay to pinpoint the CtBP2 interaction site in acinus-S. Immunoprecipitation assay revealed that the full-length protein and the CTD fragments (aa 228–583, aa 340–583) of acinus strongly associated with CtBP2; in contrast, the NTD (aa 1–340) of acinus failed, suggesting that acinus aa 340–583 is the major binding region for CtBP2 (Figures 1c and d).

NAD+ is essential for acinus-S/CtBP2 association

NAD+/NADH ratio modulates the function of CtBP proteins (Kumar et al., 2002; Zhang et al., 2002; Fjeld et al., 2003; Thio et al., 2004; Garriga-Canut et al., 2006). To test if NAD+ or NADH is necessary for CtBP2/acinus-S interaction, we performed an in vitro binding assay in the presence of 100 μM NAD+ or NADH. CtBP2 associated with acinus-S in the presence of NAD+, but not NADH or vehicle control (Figure 2a, first panel). However, neither NAD+ nor NADH promoted acinus-S to bind CtBP1, suggesting that the acinus-S/CtBP association is isoform specific (Figure 2a, third panel). To test whether NAD+ binding to CtBP2 is essential for its interaction with acinus-S, we mutated the NAD+ binding site in CtBP2 (G189 into A; Thio et al., 2004) and cotransfected with acinus-S into HEK293 cells. Wild-type, but not G189A, mutant of CtBP2 coimmunoprecipitated with acinus-S, suggesting the CtBP2/acinus-S interaction is impaired when the NAD+ binding ability of CtBP2 is abolished. An irrelevant nuclear protein PIKE-A (Liu et al., 2007) was used in the transfection and immunoprecipitation as a negative control. No association between PIKE-A and acinus-S was detected, indicating the high specificity for CtBP2/acinus-S association (Figure 2b). To further confirm that acinus-S/CtBP2 interaction is regulated by NAD+ level in vivo, we stimulated HEK293 cells overexpressing CtBP2 and acinus-S with chemicals that increase the intracellular NAD+ concentrations ([NAD+]i; McLure et al., 2004; Ying et al., 2005). As anticipated, NAD and niacinamide were effective in inducing acinus-S/CtBP2 association. Together, these data suggest that NAD+ binding to CtBP2 is essential for its association with acinus-S and changes of [NAD+]i affect this interaction.

Figure 2

The association of CtBP2 and acinus-S is NAD+ dependent. (a) in vitro binding of CtBP2 and acinus-S. Flag-acinus-S associated with purified GST-CtBP2 in the presence of NAD+, but not NADH (first panel). However, neither NAD+ nor NADH enhanced the association of flag-acinus-S and GST-CtBP1 (third panel). The GST-fused CtBP2 and CtBP1 used in the in vitro binding were detected by Coomassie blue staining (2nd and fourth panels). (b) Mutation of NAD+ binding domain of CtBP2 diminishes the CtBP2/acinus-S association. Myc-tagged wild-type CtBP2, G189A mutant or PIKE-A were cotransfected with flag-acinus-S into HEK293 cells. The proteins were immunoprecipitated using anti-myc antibody and the associated acinus was detected using anti-flag antibody (top panel). No additional NAD+ was included during the immunoprecipitation. The expression of flag-acinus (middle panel) and myc-tagged proteins (lower panel) were also verified. (c) HEK293 cells were cotransfected with GST-CtBP2 and flag-acinus-S followed by a stimulation of vehicle, 10 mM NAD+ or 12.5 mM niacinamide for 24 h. The CtBP2 were then pulled down and the associated acinus-S was detected using anti-flag antibody (top panel). The expression of GST-CtBP2 and flag-acinus-S were also verified (middle and lower panels).

Binding of CtBP2 to acinus-S is regulated by NGF

We have previously reported that the association of acinus-S and zyxin is enhanced by growth factor stimulation (Chan et al., 2007). We tested if growth factor also triggers acinus-S/CtBP2 interaction. PC12 is a phenochromocytoma cell line that expresses TrkA receptor and is NGF responsive. Serum-starved PC12 cells were treated with NGF for various time points and CtBP2 was immunoprecipitated. Association of CtBP2 with acinus-S increased after 6 h stimulation and the interaction was further elevated after 24 h (Figure 3a). Pretreatment of PC12 cells with PI3K inhibitor (LY294002) or Akt inhibitor (TCN) abolished NGF-induced CtBP2/acinus-S complex. By contrast, PKC inhibitor GF109203x had no significant effect on the interaction (Figure 3b). These results suggest that NGF-induced Akt activation is able to enhance the CtBP2/acinus-S interaction. To verify that phosphorylation of acinus-S by Akt is required for CtBP2 interaction, we performed a binding assay using different acinus-S mutants (Hu et al., 2005). Although the Akt phosphorylation mimetic mutant (S422, 573D) robustly interacted with CtBP2, unphosphorylated mutant acinus-S (S422, 573A) failed (Figure 3c). in vitro phosphorylation assay showed that CtBP2 could not be phosphorylated by Akt (data not shown). Immunofluorescent staining further confirmed that CtBP2/acinus-S interaction is phosphorylation dependent. Colocalization of CtBP2 and Acinus-S was evident in the nuclear speckles of HEK293 cells transfected with CtBP2 and wild-type acinus-S or the S422, 573D mutant. In contrast, colocalization of CtBP2 and Acinus-S was significantly diminished, when acinus-S S422, 573A mutant was overexpressed (Figure 3d). Hence, acinus phosphorylation by Akt is critical for its association with CtBP2.

Figure 3

Nerve growth factor (NGF) regulates the interaction of CtBP2 and acinus-S. (a) Endogenous association of acinus-S and CtBP2 is enhanced on NGF stimulation. PC12 cells were treated with NGF (50 ng/ml) at the indicated times, CtBP2 was immunoprecipitated. The coprecipitated proteins were analysed by anti-acinus antibody (first panel). The amount of acinus-S (second panel), phosphorylated-acinus-S (third panel) and CtBP2 were also examined. (b) Blockage of PI3K/Akt pathway abolishes the acinus-S/CtBP2 interaction by NGF. PC12 cells were pretreated with GF109203x (10 μM), LY294002 (10 μM) and TCN (10 μM) for 45 min, followed by NGF treatment for 6 h. The endogenous CtBP2 was then immunoprecipitated and the associated acinus-S was detected (upper panel). The expression of CtBP2 (middle panel) and acinus-S (lower panel) in the whole cell lysates were shown. (c) Akt phosphorylation of acinus-S is essential for CtBP2 binding. HEK293 cells were cotransfected with myc-tagged CtBP2 and GST-tagged wild-type acinus, Akt unphosphorylate mutant (S422, 573A) or phosphorylation mimetic (S422, 573D). The transfected CtBP2 was immunoprecipitated and the associated acinus-S was detected using anti-GST antibody (top panel). The expression of myc-CtBP2 (middle panel) and GST-acinus-S (bottom panel) were also examined. (d) Nuclear colocalization of CtBP2 and acinus-S. HEK293 cells were cotransfected with myc-CtBP2 and various GST-acinus-S mutants. Less colocalization were found when CtBP2 was cotransfected with GST-acinus-S S422, 573A (AA) mutant, but not the wild-type (WT) or acinus-S S422, 573D (DD).

CtBP2 represses acinus-S-mediated cyclin A1 expression

As acinus-S is essential for cyclin A1 expression (Jang et al., 2008) and CtBP2 is a corepressor, we hypothesized that CtBP2 might downregulate the transcription-enhancing activity of acinus-S. To test this possibility, we cotransfected acinus-S and cyclin A1 promoter-linked luciferase reporter into HEK293 cells together with increasing amount of CtBP2. Luciferase activity was escalated, when acinus-S was overexpressed (Figure 4a, lane 2), indicating that acinus-S enhances cyclin A1 expression by acting through its promoter. CtBP2, however, diminished the stimulatory effect in a dose-dependent manner (Figure 4a, lanes 3–6), suggesting that CtBP2 acts as a repressor to acinus-S-mediated transcription. Depletion of CtBP2 using its specific siRNA that substantially increased cyclin A1 promoter activity (Figure 4b). Nonetheless, overexpression of CtBP2 or the NAD+ binding deficient mutant (G189A) did not change the promoter activity (Figure 4c, lanes 3 and 4). This is probably due to the high endogenous CtBP2 expression level in HEK293 cells. Fitting with our previous report (Jang et al., 2008), overexpression of wild-type, but not the S422, 573A, mutant (mGST-Acinus-S AA) of acinus-S enhanced the luciferase activity (Figure 4c, lanes 5 and 6). This augmentation was abolished when wild-type CtBP2 was coexpressed; in contrast, G189A mutant had no effect (Figure 4c, lane 5, 8 and 11). The luciferase activity was further increased, when acinus-S S455, 573D mutant (mGST-Acinus-S DD) was overexpressed (Figure 4c, lanes 5 and 7). Similarly, luciferase activity induced by acinus-S S422, 573D (mGST-Acinus-S DD) was reduced in the presence of wild-type, but not G189A, mutant of CtBP2 (Figure 4d, lanes 7, 10 and 13). Collectively, these findings support that CtBP2 is a repressor that downregulates acinus-S-mediated cyclin A1 expression in a NAD+-dependent manner.

Figure 4

CtBP2 downregulates acinus-S-provoked cyclin A1 promoter activity. (a) Luciferase assay by cyclin A1 promoter. Different amount of myc-CtBP2 were cotransfected with GST-acinus-S and luciferase-linked cyclin-A1 promoter in HEK293 cells. Empty vector was added to normalize the amount of DNA used in the transfection. The presence of CtBP2 diminished the promoter activity enhanced by acinus-S as indicated by the luciferase activity (top panel). The expression of CtBP2 and acinus-S were examined by immunoblotting (middle and bottom panels) (***P<0.001 vs transfection with cyclin A1 promoter alone, one-way ANOVA, n=3). (b) HEK293 cells were transfected with scramble RNA or siRNA against CtBP2, followed by cotransfection with cyclin A1-pomoter and GST-acinus-S. Depletion of CtBP2 enhances the acinus-S mediated cyclin A1 promoter activity (first panel) (***P<0.001, Student's t-test, n=3). The endogenous CtBP2 (second panel) and GST-acinus-S (third panel) were also examined. (c) Disruption of CtBP2 and acinus-S interaction abolishes the CtBP2-repressive activity on cyclin A1 promoter. HEK293 cells were transfected with luciferase-linked cyclin A1 promoter and various combinations of CtBP2 and acinus-S mutants. The cyclin A1 promoter activation was determined by the luciferase activity (top panel). The expression of various mutants was also examined (middle and bottom panels) (***P<0.001, one-way ANOVA, n=3).

CtBP2 is essential for NGF to inhibit cyclin A1 expression

Our luciferase assay results suggest that CtBP2 inhibits cyclin A1 expression by downregulating the transcriptional stimulatory activity of acinus-S. To further demonstrate the functional consequence of CtBP2/acinus-S interaction in human leukemia, we stimulated K562 cells, a cell line that specifically expresses cyclin A1 (Shankar et al., 2005) and TrkA receptor (Chevalier et al., 1994), with NGF (100 ng/ml) and monitored the CtBP2/Acinus-S association and cyclin A1 expression. The amount of cyclin A1 was significantly decreased after 6 h NGF stimulation. Further reduction of cyclin A1 expression occurred at 24 h (Figure 5a, sixth panel). By contrast, cyclin A2 and cyclin D1 remained constant throughout the experimentation, suggesting that NGF specifically downregulated cyclin A1, but not other cyclin proteins (Figure 5a, seventh and eighth panels). The association between CtBP2 and acinus-S was increased by NGF. The strongest binding was detected at 24 h (Figure 5a, first panel), which inversely correlated with the cyclin A1 expression. This result also fits with our observation in PC12 cells that NGF enhances acinus-S/CtBP2 association (Figure 3a). Akt phosphorylation peaked at 30 min. The level of Akt phosphorylation decreased afterward but remained substantially higher than the basal level at 24 h (Figure 5a, fifth panel). In agreement with the immunoblotting analysis, reverse transcription (RT)–PCR revealed that transcription of cyclin A1, but not cyclin A2, was significantly reduced after NGF stimulation for 24 h (Figure 5b).

Figure 5

Nerve growth factor (NGF) downregulates cyclin A1 expression by promoting CtBP2 and acinus-S interaction. (a) K562 cells were treated with NGF (100 ng/ml) for various time intervals as indicated. The interaction of endogenous CtBP2 and acinus-S was determined by immunoprecipitation (first panel). Equal amount of acinus-S (second panel) and CtBP2 (fourth panel) was used in the immunoprecipitation. Phosphoryaltion of acinus-S (third panel) and Akt (fifth panel) were examined to testify the action of NGF. Level of cyclin A1 was reduced after NGF stimulation (sixth panel). Cyclin D1 (eighth panel) and cyclin A2 were not affected (seventh and eighth panels). (b) NGF downregulates cyclin A1 transcription. K562 cells were treated with NGF (100 ng/ml) for various time intervals as indicated and the expression of cyclin A1 (top panel) and cyclin A2 (middle panel) were examined by reverse transcription (RT)–PCR. Equal expression of housekeeping GAPDH (bottom panel) was confirmed. (c) Overexpression of CtBP2 in K562 cells reduces cyclin A1 expression. K562 cells were transfected with myc-tagged CtBP2 or empty vector. After transfection of 24 h, the cells were stimulated with NGF (100 ng/ml) for another 24 h. The expression of endogenous cyclin A1 (upper panel) and the transfected CtBP2 (lower panel) were examined by immunoblotting. (d) Effect of CtBP2 or acinus-S depletion on cyclin A1 expression in K562 cells. K562 cells were transfected with either scramble RNA, CtBP2 or Acinus-S siRNA. The cyclin A1 protein (upper panel) was examined by immunoblotting. The knockdown efficiency of CtBP2 (middle panel) and acinus-S (bottom panel) were verified. (e) Depletion of CtBP2 abolishes NGF-suppressed cyclin A1 transcription. siRNA-transfected K562 cells were treated with NGF (50 ng/ml) for 24 h and the expression of cyclin A1 (upper panel) and cyclin A2 (lower panel) were examined by RT–PCR. (f) NGF inhibits K562 cell proliferation. After treatment by NGF with indicated concentration for 48 h, the total number of cells was determined by trypan blue exclusion assay. Results were normalized and expressed as the percentage of the control group (*P<0.05, one-way ANOVA, n=3).

To further demonstrate the effect of CtBP2 and acinus-S on cyclin A1 expression, we transfected K562 cells with myc-CtBP2 and stimulated the cells with NGF. Compared with control, the amount of the endogenous cyclin A1 was markedly reduced in CtBP2 overexpressed cells. NGF treatment further diminished cyclin A1 level (Figure 5c).

NGF significantly blocked cyclin A1 expression after 24 h, and this inhibition was abolished when CtBP2 was depleted by its siRNA. Moreover, the expression of cyclin A1 was markedly enhanced in CtBP2-deficient cells (Figure 5d, top panel), suggesting that CtBP2 is a major factor in repressing cyclin A1 expression in both basal and growth factor-stimulated fashions. On the other hand, knocking down of acinus-S abolished cyclin A1 expression, which was slightly reduced on NGF stimulation (Figure 5d, top panel), indicated that acinus is a critical effector to regulate cyclin A1 expression by NGF. The modest reduction effect by NGF in acinus-depleted cells might be due to the remnant acinus that was not completely eradicated by its siRNA (Figure 5d, bottom panel). Similarly, transcription of cyclin A1, but not the cyclin A2, was reduced by NGF in control cells, but not in CtBP2-depleted K562 cells (Figure 5e). Depletion of acinus-S also diminished the expression of cyclin A1, but not A2 (Figure 5e).

As depletion of cyclin A1 significantly reduce proliferation in leukemia cells (Ji et al., 2005), treatment of K562 cells with NGF would therefore trigger similar effect. Titration assay revealed that NGF prevented K562 cell proliferation in a dose-dependent manner. NGF at a low concentration of 5, 10 or 50 ng/ml did not affect the cell proliferation (Figure 5f). However, when NGF concentration was increased to 100 and 500 ng/ml, cell proliferation was inhibited to approximately 75% of control. No significant amount of cell death was observed in all NGF-treated cells, indicating that the reduction of cell number was not a result of extensive cell death (data not shown). These results suggested that the downregulation of cyclin A1 by NGF leads to a reduction of cell proliferation.

TrkA agonist gambogic amide inhibits leukemia cell proliferation

NGF has poor pharmacokinetic properties. It has a very short distribution half-life of about 5.4 min in circulation (Tria et al., 1994). We therefore tested the antiproliferative function of NGF using its mimetic GA-amide (Jang et al., 2007) in leukemic mice model. As shown in Figure 6a, stimulation of K562 cells with GA-amide for 30 min activated the TrkA phosphorylation in a concentration as low as 40 nM. The expression of cyclin A1, but not cyclin A2, was inhibited when the cells were challenged by GA-amide for 24 h. Significant reduction of cyclin A1 was observed when 80 or 100 nM of GA-amide was used (Figure 6b). Similar to NGF, GA-amide enhanced the formation of CtBP2/acinus-S complex (Figure 6c) and prolonged treatment for 48 h, significantly inhibiting cells proliferation (Figure 6d). Titration assay revealed that cell proliferation was reduced to about 50% at 60 nM GA-amide stimulation. Moreover, GA-amide altered the cell-cycle status of K562 cells (Figure 6e). The G1/S transition was significantly reduced in GA-treated K562 cells (G1: 45.8±0.3 vs 36.5±0.1; S: 20.7±0.2 vs 16.6±0.2). In contrast, the number of K562 cells in G2/M phase after GA-amide stimulation was augmented (14.7±0.5 vs 21.9±0.1), indicating GA-amide induces a G2/M arrest in K562 cells. This cell-cycle pattern resembles to previous finding that downregulation of cyclin A1 in ML1 leukemic cells by siRNA challenge slowed S phase entry with G2/M phase accumulation (Ji et al., 2005). Intraperitoneal (i.p.) injection of normal mice with GA-amide (2 mg/kg) induced TrkA phosphorylation in brain 1 h after injection and peaked at 4 h, and the phosphorylation sustained till 8 h (Figure 6f), suggesting that the GA-amide is effective in triggering TrkA activation in mice.

Figure 6

TrkA agonist gambogic amide (GA-amide) inhibits K562 cells proliferation and ameliorates leukemia progression. (a) GA-amide triggers TrkA phosphorylation in vitro. K562 cells were stimulated with different concentrations of GA-amide as indicated for 30 min. The phosphorylation of TrkA and total TrkA amount were examined by western blot analysis. (b) GA-amide reduces cyclin A1, but not cyclin A2, expression. K562 cells were stimulated with different concentration of GA-amide as indicated for 24 h. (c) GA-amide enhances CtBP2/acinus-S interaction. K562 cells were stimulated with 200 nM GA-amide for 24 h. The CtBP2 was immunoprecipitated and the associated acinus-S was tested using specific antibody (top panel). The expressions of CtBP2 (middle panel) and acinus-S (bottom panel) were also examined. (d) GA-amide inhibits K562 cells proliferation. Various concentrations of GA-amide were applied to K562 cell culture for 48 h. The number of living K562 cells were examined by trypan blue exclusion assay. Results were mean±s.e.m. from three independent experiments (*P<0.05, one-way ANOVA). (e) Cell-cycle analysis of K562 cells treated with 100 nM GA-amide for 48 h (***P<0.001, Student's t-test, n=3). (f) GA-amide triggers TrkA phosphorylation in vivo. Three-month-old C57BL6 mice were injected with 2 mg/kg GA-amide intraperitoneally and scarified at different time intervals as indicated. The phosphorylation and total expression of TrkA in brain was examined by western blot analysis. (g) Reduced splenomegaly in GA-amide-injected leukemic mice. After 3 weeks injection of GA-amide (2 mg/kg, daily i.p. injection), the K562 cell-inoculated nude mice were scarified and the spleen weight was measured. Data were expressed as mean±s.e.m. from six animals in each treatment group (*P<0.05, Student's t-test). (h) Immunohistochemical staining of spleen tissues collected from K562-inoculated nude mice treated with saline or 2 mg/kg GA-amide. The tissues were staining with antibody against the K562 marker (human CD45). Magnified view shown in the right panel of each pulp was marked with dash rectangle. Representative result of three mice from each treatment was shown. (i) Proposed mechanistic model of nerve growth factor (NGF)-repressed cyclin A1 expression.

Next, we investigated the effect of GA-amide in leukemia progression in nude mice inoculated with K562 cells. All K562-inoculated mice remained alive throughout the experimentation. However, the spleen weights of both K562-inoculated nude mice were significantly reduced when GA-amide was administrated (Figure 6g). We further assessed the leukemia progression in the nude mice by examining the presence of K562 cells in the spleen of the mice by immunohistochemical staining. Infiltrations of K562 cells were detected in both white and red pulp of the spleen of saline injected mice. However, no K562 cells were found in the white pulp and only a small number of K562 were detected in the red pulp of GA-amide-administrated mice (Figure 6h). Collectively, these results suggested that GA-amide administration could reduce the in vitro leukemia cell proliferation and ameliorate the leukemia progression in vivo.


CtBP1 is a D2-hydroxyacid dehydrogenase using NAD+ as the cofactor (Kumar et al., 2002). Binding of NAD+ or NADH to CtBPs not only triggers their enzymatic action but also affects their corepressor activity. It has been reported that NADH is critical for CtBP1 and -2 to interact with HIC1 and diminish its repression on SIR1 expression (Hong et al., 2007). Similarly, mutation of the NAD+ binding site in CtBP2 abolishes its homodimization as well as repression activity in the Gal4 tethering assay (Thio et al., 2004). Our results provide further evidence for the critical role of NAD+ to CtBP2 function. First, the presence of NAD+, but not NADH, is essential for the in vitro interaction between acinus-S and CtBP2 (Figure 1a). Second, chemicals that increase cellular NAD level, such as niacinamide, are able to enhance their interaction in vivo (Figure 2c). Furthermore, mutation of the NAD+ binding site in CtBP2 abolishes the interaction in intact cells (Figure 2b), thus inhibiting the repressive activity of CtBP2 on cyclin A1 promoter activation by acinus-S (Figure 4c). It is noteworthy that the changes of cellular NAD+ level also contribute to NGF-induced CtBP2/acinus-S complex formation, as NGF increases NAD+ concentration in PC12 cells (Jackson et al., 1992). Presumably, NGF triggers the phosphorylation of acinus-S by Akt on one hand, and increases the cellular NAD+ level to enhance CtBP2 binding activity on the other hand, which synergistically increases the association between acinus-S and CtBP2.

The identification of CtBP as the interaction partner of viral protein E1a suggests that the corepressor favorably associates with protein containing a short motif with aa PLDLS (Boyd et al., 1993). Later studies reveal that similar motif is conserved in a lot of CtBP binding proteins such as FOG-2 (Fox et al., 1999) and BKLF (Turner and Crossley, 1998), and mutation of the motif abolishes the interaction. Surprisingly, there is no similar motif in acinus-S, indicating that a nonclassical interaction occurs between CtBP2 and acinus-S. Indeed, our in vitro binding assay suggests that an overall tertiary structure rather than a specific motif of CtBP2 is necessary for CtBP2/acinus-S complex formation (Figure 1b). Although the structure of CtBP2 has not been reported, crystal structure of CtBP1 shows that it is a dumbbell-shaped protein contained a large and a small domain separated by the hinge region (Kumar et al., 2002). The small domain (or referred as substrate binding domain) composes of the residues from both N- and C termini. As both N- and C termini of CtBP2 interact with acinus-S, it is thus reasonable to infer that the substrate binding domain is responsible for the CtBP2/acinus-S association. It has been suggested that the C terminus of CtBPs maintains an unstructured conformation, which might be instrumental for its recognition and binding to diverse molecular partners (Nardini et al., 2006). This observation might explain the unsuccessful interaction between full-length CtBP2 and acinus-S in vitro (Figure 1a), which could be rescued in the presence of NAD+ (Figure 2a). As conformational change on NAD+ binding is a key feature of NAD+-dependent dehydrogenase (De Weck et al., 1987), binding of NAD+ to CtBP2 would somehow stabilize the C-terminal structure of CtBP2, which favors its binding to acinus-S.

Acinus proteins are a part of splicing machinery (Schwerk et al., 2003), however, their roles in mRNA transcription have not been well studied. We have reported that acinus-S is essential for cyclin A1 expression, which provides the first evidence that these proteins regulate gene transcription (Jang et al., 2008). Recently, Vucetic et al. (2008) reported that acinus-S′, another isoform of acinus-S, interacted with RAR and repressed RAR-regulated gene expression such as CYP26. These results suggest that acinus proteins could function as a transcription repressor or activator in a gene-specific manner. Yet the detailed mechanism of how acinus proteins control gene transcription remains to be studied; our findings that CtBP2 inhibits the transcriptional enhancer activity of acinus-S provide further insight into this process. Conceivably, the transcriptional activity of acinus proteins could be modulated by cooperating with various nuclear proteins to achieve a particular physiological function.

As cell-cycle arrest is critical for cell differentiation (Miller et al., 2007), our results that NGF inhibits proliferation via CtBP2/acinus-S/cyclin A1 pathway might provide a prerequisite mechanism for K562 differentiation. It is noteworthy that NGF also enhances proliferation of TF1 erythroleukemia cells (Chevalier et al., 1994). Moreover, a recent study reported that neutrophin receptors (Trk) are constitutively activated and induce leukemogenesis in blasts from patients with acute myeloid leukemia (Li et al., 2009). One of the possible explanations to this discrepant role of TrkA lies on the differential signaling cascade activation. It has been reported that PI3K and mTOR, but not Akt, are the decisive transformation pathways for mutated TrkA-mediated leukemogenesis (Meyer et al., 2007). Activation of Akt, however, is necessary for CtBP2/acinus-S interaction and its subsequent cyclin-A1 suppression. Conceivably, NGF might have dual functions in the hematopoiesis that it triggers either proliferation or differentiation in a cell-type-specific and signaling cascade-specific manner.

GA-amide is a TrkA agonist, which mimics the physiological functions of NGF in protecting the neurons from apoptotic stress (Jang et al., 2007). In this report, we have demonstrated that GA inhibits K562 cells proliferation and reduces leukemia progression in mice (Figure 6). These results suggest that GA-amide can be an effective agent for inhibiting cancer cell proliferation in vivo and highlights its therapeutic potential in leukemia treatment. Indeed, gambogic acid and its derivatives have been reported to inhibit proliferation of tumor cells in a variety of tissues (Guo et al., 2004; Liu et al., 2005; Tao et al., 2007; Chen et al., 2008; Qiang et al., 2008; Shu et al., 2008; Xu et al., 2009). Interestingly, our finding that NGF or GA-amide inhibits cell growth is contradictory to the well-recognized antiapoptotic function of NGF. The antitumorigenic activity of NGF, however, has been reported in pituitary adenomas, small cell lung cancer, prostate cancer and thyroid tumor (Missale et al., 1993, 1998; Sigala et al., 1999; Paez Pereda et al., 2000), which further supports the notion that NGF can act as an inhibitor to cell proliferation.

In summary, we have provided evidence that NGF enhances the interaction of CtBP2 and acinus-S, which reduces the expression of cyclin A1, leading to inhibited proliferation of leukemia cells (Figure 6i). By using the NGF mimetic compound GA-amide, we demonstrated that systemic administration of GA-amide effectively inhibits the leukemia progression. Therefore, GA-amide might be a potential therapeutic agent against leukemia.

Materials and methods

Animal experiment

Animal experiments were conducted according to the institutional ethical guidelines for animal experiments and approved by the Institutional Animal Care and Use Committee at Emory University. Six-week-old nude mice (athymic nu/nu; Totonic, Hudson, NY, USA) were irradiated (1 × 550 cGy) and tail vein injected with 1 × 106 K562 cells suspended in 0.6 ml Hanks’ balanced salt solution. One week after K562 inoculation, 2 mg/kg GA-amide were injected (i.p.) daily for 3 weeks.

Yeast two-hybrid screening

The experiments were executed exactly as described (Ye et al., 1999).

Coimmunoprecipitation and in vitro binding assay

Experimental procedures for coimmunoprecipitation and in vitro binding assays are as described (Ye et al., 1999). Western blotting analysis was performed with a variety of antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA; cyclin A2, cyclin D1 and Trk), BD Pharmingen (San Diego, CA, USA; CtBP2 and cyclin A1), Cell Signaling Technology, Inc. (Davers, MA, USA; phosphor-Akt S473 and phosphor-TrkY490) and Millipore Corporate (Billerica, MA, USA; acinus).

Luciferase assay

HEK293 cells were cotransfected with CtBP2, and acinus-S plasmids with the pGL3 plasmid consisting of cyclin A1 promoter as previously described (Jang et al., 2008). Luciferase activity of cell lysates was then determined using Dual Luciferase Assay Kit (Promega Corporation, Madison, WI, USA).


Total RNA from was prepared by using Trizol Isolation Reagent (Invitrogen Corporation, Carlsbad, CA, USA). Total RNA (5 μg) were extracted and first-strand cDNA was synthesized by using Superscript III reverse transcriptase (Invitrogen) and Oligo-dT17 as primer with recommended procedures. Amplification of cyclin A1 and cyclin A2 were performed using the following primers: cycin A1-RT5 (5′-IndexTermGCCTGGCAAACTATACTGTG-3′), cyclin A1-RT3 (5′-IndexTermCTCCATGAGGGACACACACA-3′), cyclin A2-RT5 (5′-IndexTermTCCATGTCAGTGCTGAGAGGA-3′) and cyclin A2-RT3 (5′-IndexTermGAAGGTCCATGAGAGAAGGC-3′). GAPDH fragment was also amplified as internal standard using primers GAPDH-F (5′-IndexTermCGCATCTTCTTGTGCAGTGCC-3′) and GAPDH-R (5′-IndexTermGGCCTTGACTGTGCCGTTGAATTT-3′). A kinetic profile of the amount of PCR product generated at different PCR cycles was constructed and the cycle number used for individual gene expression study was chosen within the exponential region of the amplification curve. This is to ensure that the amount of the PCR product reflects the amount of template in the original sample.

Immunohistochemical staining

Immunohistochemical assays were performed on formalin-fixed paraffin-embedded sections. Sections from spleen were cut, deparaffinized in xylene and rehydrated in graded alcohols. The slides were then treated with 0.3% hydrogen peroxide and SuperBlock blocking buffer (Thermo Fisher Scientific Inc., Rockford, IL, USA), and incubated with mAb against human CD45 (BD Biosciences, San Jose, CA, USA). Finally, horseradish peroxidase activity was detected by Zymed Histostain Kit (Invitrogen) and the cells were counterstained with hematoxylin.

Cell-cycle analysis

K562 cells were treated with either phosphate-buffered saline or 100 nM GA-amide for 48 h. The cells were then fixed and stained with 1 μM propidium iodide for 45 min. Cell-cycle status was examined using flow cytometry.

Statistics analysis

Data are presented as mean±s.e.m. Statistical evaluation was carried out by Student's t-test or one-way ANOVA. Data were considered statistically significant when P<0.05. All statistical analysis was performed by the computer program Prism (GraphPad Software, La Jolla, CA, USA).

Conflict of interest

The authors declare no conflict of interest.


  1. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G . (1993). A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 12: 469–478.

    CAS  Article  Google Scholar 

  2. Chan CB, Liu X, Tang X, Fu H, Ye K . (2007). Akt phosphorylation of zyxin mediates its interaction with acinus-S and prevents acinus-triggered chromatin condensation. Cell Death Differ 14: 1688–1699.

    CAS  Article  Google Scholar 

  3. Chen J, Gu HY, Lu N, Yang Y, Liu W, Qi Q et al. (2008). Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sci 83: 103–109.

    CAS  Article  Google Scholar 

  4. Chevalier S, Praloran V, Smith C, MacGrogan D, Ip NY, Yancopoulos GD et al. (1994). Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood 83: 1479–1485.

    CAS  Google Scholar 

  5. De Weck Z, Pande J, Kagi JH . (1987). Interdependence of coenzyme-induced conformational work and binding potential in yeast alcohol and porcine heart lactate dehydrogenases: a hydrogen-deuterium exchange study. Biochemistry 26: 4769–4776.

    CAS  Article  Google Scholar 

  6. Fjeld CC, Birdsong WT, Goodman RH . (2003). Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 100: 9202–9207.

    CAS  Article  Google Scholar 

  7. Fox AH, Liew C, Holmes M, Kowalski K, Mackay J, Crossley M . (1999). Transcriptional cofactors of the FOG family interact with GATA proteins by means of multiple zinc fingers. EMBO J 18: 2812–2822.

    CAS  Article  Google Scholar 

  8. Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender RM et al. (2006). 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 9: 1382–1387.

    CAS  Article  Google Scholar 

  9. Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L . (2004). General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin 25: 769–774.

    CAS  PubMed  Google Scholar 

  10. Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY et al. (2007). Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 293: E1687–E1696.

    CAS  Article  Google Scholar 

  11. Hu Y, Yao J, Liu Z, Liu X, Fu H, Ye K . (2005). Akt phosphorylates acinus and inhibits its proteolytic cleavage, preventing chromatin condensation. EMBO J 24: 3543–3554.

    CAS  Article  Google Scholar 

  12. Jackson GR, Werrbach-Perez K, Ezell EL, Post JF, Perez-Polo JR . (1992). Nerve growth factor effects on pyridine nucleotides after oxidant injury of rat pheochromocytoma cells. Brain Res 592: 239–248.

    CAS  Article  Google Scholar 

  13. Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P et al. (2007). Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci USA 104: 16329–16334.

    CAS  Article  Google Scholar 

  14. Jang SW, Yang SJ, Ehlen A, Dong S, Khoury H, Chen J et al. (2008). Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. Cancer Res 68: 4559–4570.

    CAS  Article  Google Scholar 

  15. Ji P, Agrawal S, Diederichs S, Baumer N, Becker A, Cauvet T et al. (2005). Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene 24: 2739–2744.

    CAS  Article  Google Scholar 

  16. Kaebisch A, Brokt S, Seay U, Lohmeyer J, Jaeger U, Pralle H . (1996). Expression of the nerve growth factor receptor c-TRK in human myeloid leukaemia cells. Br J Haematol 95: 102–109.

    CAS  Article  Google Scholar 

  17. Kaplan DR, Stephens RM . (1994). Neurotrophin signal transduction by the Trk receptor. J Neurobiol 25: 1404–1417.

    CAS  Article  Google Scholar 

  18. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC et al. (2005). Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 115: 2716–2730.

    CAS  Article  Google Scholar 

  19. Katsanis N, Fisher EM . (1998). A novel C-terminal binding protein (CTBP2) is closely related to CTBP1, an adenovirus E1A-binding protein, and maps to human chromosome 21q21.3. Genomics 47: 294–299.

    CAS  Article  Google Scholar 

  20. Kramer A, Hochhaus A, Saussele S, Reichert A, Willer A, Hehlmann R . (1998). Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation. Leukemia 12: 893–898.

    CAS  Article  Google Scholar 

  21. Kumar V, Carlson JE, Ohgi KA, Edwards TA, Rose DW, Escalante CR et al. (2002). Transcription corepressor CtBP is an NAD(+)-regulated dehydrogenase. Mol Cell 10: 857–869.

    CAS  Article  Google Scholar 

  22. Li Z, Beutel G, Rhein M, Meyer J, Koenecke C, Neumann T et al. (2009). High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 113: 2028–2037.

    CAS  Article  Google Scholar 

  23. Liao C, Wang XY, Wei HQ, Li SQ, Merghoub T, Pandolfi PP et al. (2001). Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci USA 98: 6853–6858.

    CAS  Article  Google Scholar 

  24. Liu W, Guo QL, You QD, Zhao L, Gu HY, Yuan ST . (2005). Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol 11: 3655–3659.

    CAS  Article  Google Scholar 

  25. Liu X, Hu Y, Hao C, Rempel SA, Ye K . (2007). PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion. Oncogene 26: 4918–4927.

    CAS  Article  Google Scholar 

  26. McLure KG, Takagi M, Kastan MB . (2004). NAD+ modulates p53 DNA binding specificity and function. Mol Cell Biol 24: 9958–9967.

    CAS  Article  Google Scholar 

  27. Meyer J, Rhein M, Schiedlmeier B, Kustikova O, Rudolph C, Kamino K et al. (2007). Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA. Leukemia 21: 2171–2180.

    CAS  Article  Google Scholar 

  28. Miller JP, Yeh N, Vidal A, Koff A . (2007). Interweaving the cell cycle machinery with cell differentiation. Cell Cycle 6: 2932–2938.

    CAS  Article  Google Scholar 

  29. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R et al. (1993). Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 90: 7961–7965.

    CAS  Article  Google Scholar 

  30. Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M, Sher E et al. (1998). Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci USA 95: 5366–5371.

    CAS  Article  Google Scholar 

  31. Nardini M, Svergun D, Konarev PV, Spano S, Fasano M, Bracco C et al. (2006). The C-terminal domain of the transcriptional corepressor CtBP is intrinsically unstructured. Protein Sci 15: 1042–1050.

    CAS  Article  Google Scholar 

  32. Paez Pereda M, Missale C, Grubler Y, Arzt E, Schaaf L, Stalla GK . (2000). Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol 167: 99–106.

    CAS  Article  Google Scholar 

  33. Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF et al. (2008). Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol 75: 1083–1092.

    CAS  Article  Google Scholar 

  34. Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoneda Y, Tsujimoto Y . (1999). Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 401: 168–173.

    CAS  Article  Google Scholar 

  35. Schwerk C, Prasad J, Degenhardt K, Erdjument-Bromage H, White E, Tempst P et al. (2003). ASAP, a novel protein complex involved in RNA processing and apoptosis. Mol Cell Biol 23: 2981–2990.

    CAS  Article  Google Scholar 

  36. Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A et al. (2005). The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 7: 351–362.

    CAS  Article  Google Scholar 

  37. Shu W, Chen Y, Li R, Wu Q, Cui G, Ke W et al. (2008). Involvement of regulations of nucleophosmin and nucleoporins in gambogic acid-induced apoptosis in Jurkat cells. Basic Clin Pharmacol Toxicol 103: 530–537.

    CAS  Article  Google Scholar 

  38. Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E et al. (1999). Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin Cancer Res 5: 1211–1218.

    CAS  PubMed  Google Scholar 

  39. Skaper SD . (2008). The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 7: 46–62.

    CAS  Article  Google Scholar 

  40. Tange TO, Shibuya T, Jurica MS, Moore MJ . (2005). Biochemical analysis of the EJC reveals two new factors and a stable tetrameric protein core. RNA 11: 1869–1883.

    CAS  Article  Google Scholar 

  41. Tao Z, Zhou Y, Lu J, Duan W, Qin Y, He X et al. (2007). Caspase-8 preferentially senses the apoptosis-inducing action of NG-18, a Gambogic acid derivative, in human leukemia HL-60 cells. Cancer Biol Ther 6: 691–696.

    CAS  Article  Google Scholar 

  42. Thio SS, Bonventre JV, Hsu SI . (2004). The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain. Nucleic Acids Res 32: 1836–1847.

    CAS  Article  Google Scholar 

  43. Tria MA, Fusco M, Vantini G, Mariot R . (1994). Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 127: 178–183.

    CAS  Article  Google Scholar 

  44. Tsuda T, Wong D, Dolovich J, Bienenstock J, Marshall J, Denburg JA . (1991). Synergistic effects of nerve growth factor and granulocyte-macrophage colony-stimulating factor on human basophilic cell differentiation. Blood 77: 971–979.

    CAS  PubMed  Google Scholar 

  45. Turner J, Crossley M . (1998). Cloning and characterization of mCtBP2, a co-repressor that associates with basic Kruppel-like factor and other mammalian transcriptional regulators. EMBO J 17: 5129–5140.

    CAS  Article  Google Scholar 

  46. Vucetic Z, Zhang Z, Zhao J, Wang F, Soprano KJ, Soprano DR . (2008). Acinus-S’ represses retinoic acid receptor (RAR)-regulated gene expression through interaction with the B domains of RARs. Mol Cell Biol 28: 2549–2558.

    CAS  Article  Google Scholar 

  47. Wolgemuth DJ, Lele KM, Jobanputra V, Salazar G . (2004). The A-type cyclins and the meiotic cell cycle in mammalian male germ cells. Int J Androl 27: 192–199.

    CAS  Article  Google Scholar 

  48. Xie P, Chan FS, Ip NY, Leung M . (2000). Nerve growth factor potentiated the sodium butyrate- and PMA-induced megakaryocytic differentiation of K562 leukemia cells. Leuk Res 24: 751–759.

    CAS  Article  Google Scholar 

  49. Xie P, Cheung WM, Ip FC, Ip NY, Leung MF . (1997). Induction of TrkA receptor by retinoic acid in leukaemia cell lines. Neuroreport 8: 1067–1070.

    CAS  Article  Google Scholar 

  50. Xu X, Liu Y, Wang L, He J, Zhang H, Chen X et al. (2009). Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells. Int J Dermatol 48: 186–192.

    CAS  Article  Google Scholar 

  51. Yang R, Morosetti R, Koeffler HP . (1997). Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res 57: 913–920.

    CAS  PubMed  Google Scholar 

  52. Yang R, Nakamaki T, Lubbert M, Said J, Sakashita A, Freyaldenhoven BS et al. (1999). Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood 93: 2067–2074.

    CAS  Google Scholar 

  53. Ye K, Compton DA, Lai MM, Walensky LD, Snyder SH . (1999). Protein 4.1N binding to nuclear mitotic apparatus protein in PC12 cells mediates the antiproliferative actions of nerve growth factor. J Neurosci 19: 10747–10756.

    CAS  Article  Google Scholar 

  54. Ying W, Alano CC, Garnier P, Swanson RA . (2005). NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res 79: 216–223.

    CAS  Article  Google Scholar 

  55. Zhang Q, Piston DW, Goodman RH . (2002). Regulation of corepressor function by nuclear NADH. Science 295: 1895–1897.

    CAS  Google Scholar 

Download references


This work is supported by a grant from NIH (RO1 NS060680) to K Ye. We thank Dr G Chinnadurai (Saint Louis University Health Sciences Center) for GST-CtBP1 plasmid.

Author information



Corresponding author

Correspondence to K Ye.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chan, C., Liu, X., Jang, SW. et al. NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association. Oncogene 28, 3825–3836 (2009).

Download citation


  • acinus
  • CtBP2
  • cyclin A1
  • gambogic amide
  • leukemia
  • NGF

Further reading


Quick links